BEST PRACTICE & RESEARCH CLINICAL HEMATOLOGY 发表评论文章，将最新原创研究文章的结果整合到实用的、基于证据的评论文章中。这些文章旨在解决诊断、治疗和患者管理的关键临床问题。每个问题都遵循以问题为导向的方法，重点关注要解决的关键问题，明确定义已知和未知的内容，涵盖临床和实验室血液学实践和研究的范围。尽管邀请了大多数评论，但编辑欢迎潜在作者的建议。

The journal 'Best Practice and Research: Clinical Haematology' publishes articles that integrate the latest original research findings into practical, evidence-based reviews. These reviews aim to address key clinical issues in diagnosis, treatment, and patient management. Each issue follows a problem-oriented approach, focusing on critical questions that need to be addressed, clearly defining known and unknown aspects, and covering the scope of clinical and laboratory hematology practice and research. While most reviews are invited, the editors welcome suggestions from potential authors.

《Best Practice and Research: Clinical Haematology》期刊发表的文章将最新的原创研究成果整合成实用的、基于证据的评论。这些评论旨在解决诊断、治疗和患者管理中的关键临床问题。每期都采用以问题为导向的方法，重点关注需要解决的关键问题，明确已知与未知的内容，涵盖临床和实验室血液学的实践与研究。虽然大多数评论是邀请撰写的，编辑也欢迎潜在作者的建议。

Best Practice and Research: Clinical Haematology

Despite high cure rates in children, acute lymphoblastic leukemia (ALL) remains a leading cause of cancer death in the young, and the likelihood of treatment failure increases with age. With the exception of tyrosine kinase inhibitors, there have been few advances in repurposing or developing new therapeutic approaches tailored to vulnerabilities of ALL subtypes or individual cases. Large-scale genome profiling studies conducted over the last decade promise to improve ALL outcomes by refining risk stratification and modulation of therapeutic intensity, and by identifying new targets and pathways for immunotherapy. Many of these approaches have been validated in preclinical models and now merit testing in clinical trials. This review discusses the advances in our understanding of the genomic taxonomy and ontogeny of B-progenitor ALL, with an emphasis on those discoveries of clinical importance.

Charles G Mullighan

Best practice & research. Clinical haematology

Best Pract Res Clin Haematol

How advanced are we in targeting novel subtypes of ALL?

Close HLA matching of donors and recipients has been the dogma for successful allogeneic blood or marrow transplantation (BMT), to limit the complications of graft rejection and graft-versus-host disease (GVHD). However, many patients in need, especially those in certain racial and ethnic groups such as African-Americans and Hispanics, are unable to find matches despite increased availability of unrelated donors. Unfortunately, despite many early attempts to develop safe, related haploidentical allogenic BMT, mortality rates exceeding 50% from severe GVHD led most centers to steer away from such transplants by the mid-1990s. However, recent advances based largely on the development of high-dose post-transplant cyclophosphamide GVHD prophylaxis, now yield results with haploidentical related donors that approach those with matched donors. With emerging data that younger donor age may be the most important donor selection criterion, HLA-mismatched donors may even have advantages over matched donors in certain situations. Although the exact role that haploidentical donors should play in donor selection strategies is still being defined, the lack of an HLA-matched donor should no longer ever be an exclusion for allogeneic BMT. Unfortunately, this progress in donor availability has not yet been fully recognized by the medical community. Such a discordance between new advances and their clinical translation highlights that changing standard practice is difficult and takes longer than it should, at least in part because it requires "unlearning" long-standing behaviors.

Richard J. Jones

Best Practice & Research Clinical Haematology

Best Practice &amp; Research Clinical Haematology

Is post-transplant cyclophosphamide a true game-changer in allogeneic transplantation: The struggle to unlearn

移植后环磷酰胺是否真正改变了异基因移植：努力摆脱固有观念的挣扎

Jiasheng Wang

Paolo F. Caimi

CAR Assembly Line: Taking CAR T-Cell Manufacturing to the Next Level

CAR组装线：将CAR T细胞制造提升到新高度

Katharina Fleischhauer

Erratum to “Special issue 37.2 and 37.3 Genetics and Function of HLA and immune-related genes in transplantation and cellular immunotherapy” [Best Pract Res Clin Haematol (2024) 101588]

《更正声明：“第37.2期和37.3期特刊：移植和细胞免疫治疗中HLA及相关免疫基因的遗传学与功能” [最佳实践与临床血液学（2024年）101588]》

Nodular marginal zone lymphoma (NMZL) is a small B-cell lymphoma involving only lymph nodes and is the least common form of MZL constituting about 10% of cases. Patients usually present with advanced disease which must be distinguished from extranodal MZL with lymph node spread. NMZL shares cytological and immunophenotypic features with MALT and splenic MZL , but has a less favorable prognosis than these two categories. It occurs mostly in adults and pediatric cases are rare. Different therapeutic approaches have been used in NMZL, but because of the small patient numbers involved, more definitive treatment is still anticipated. Recent studies suggest that it probably represents a separate entity within the broader indolent lymphoma category. In NMZL there is an emerging need to utilize novel agents, already available for indolent lymphomas. Prospective studies are required to evaluate their therapeutic efficacy for NMZL in the future.

Tamar Tadmor

Aaron Polliack

Nodal marginal zone lymphoma: Clinical features, diagnosis, management and treatment

结外边缘区淋巴瘤：临床特征、诊断、管理和治疗

Special Issue 37.3: “Genetics and Function of HLA and immune-related genes in transplantation and immunotherapy”

特刊37.3: “HLA及免疫相关基因在移植与免疫治疗中的遗传学与功能”

Thuong Hien Tran

Andreas Heinold

Magdalena Spackova

Lien Pham

Matthias Stelljes

Peter Dreger

Relevance of donor-specific HLA antibodies in hematopoietic cell transplantation

造血干细胞移植中供者特异性HLA抗体相关性

Esteban Arrieta-Bolaños

From clones to immunopeptidomes: new developments in the characterization of permissive HLA-DP mismatches in hematopoietic cell transplantation

从克隆到免疫肽组：造血细胞移植中允许性HLA-DP错配表征的新进展

Abbreviation	Best. Pract. Res. Clin. Haematol.
Journal Impact	2.21
Quartiles(Global)	HEMATOLOGY(Q3)

ISSN	1521-6926, 1532-1924
h-index	81

Publication Information	Publisher: Bailliere Tindall Ltd，Publishing cycle: Quarterly，Journal Type: journal，Open Access Journals: No
Basic data	Year of publication: 1999，Proportion of original research papers: 97.62%，Self Citation Rate:0.00%， Gold OA Rate: 16.08%
Average review cycle	网友分享经验：>12周，或约稿
Average recruitment ratio	网友分享经验：较易

Best Practice and Research: Clinical Haematology

Journal Citation Format

A journal article with 1 author

A journal article with 2 authors

A journal article with 3 authors

A journal article with 5 or more authors

Books Citation Format

Thesis Citation Format

Web sites Citation Format

Patent Citation Format

Staying up late manually editing references? ivySCI automatically matches journals and helps you generate references with a single click.

Share Submission Experience

How advanced are we in targeting novel subtypes of ALL?

Is post-transplant cyclophosphamide a true game-changer in allogeneic transplantation: The struggle to unlearn

CAR Assembly Line: Taking CAR T-Cell Manufacturing to the Next Level

Erratum to “Special issue 37.2 and 37.3 Genetics and Function of HLA and immune-related genes in transplantation and cellular immunotherapy” [Best Pract Res Clin Haematol (2024) 101588]

Nodal marginal zone lymphoma: Clinical features, diagnosis, management and treatment

CAR Assembly Line: Taking CAR T-Cell Manufacturing to the Next Level

Erratum to “Special issue 37.2 and 37.3 Genetics and Function of HLA and immune-related genes in transplantation and cellular immunotherapy” [Best Pract Res Clin Haematol (2024) 101588]

Special Issue 37.3: “Genetics and Function of HLA and immune-related genes in transplantation and immunotherapy”

Relevance of donor-specific HLA antibodies in hematopoietic cell transplantation

From clones to immunopeptidomes: new developments in the characterization of permissive HLA-DP mismatches in hematopoietic cell transplantation